<DOC>
	<DOC>NCT00317356</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of OPC-6535 (tetomilast) and to determine its optimal dose by once-daily oral administration at 0, 12.5, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-ASA) in patients with active ulcerative colitis.</brief_summary>
	<brief_title>A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients with active ulcerative colitis Patients who have been receiving an oral 5ASA formulation at a fixed regimen and at a fixed dose Either inpatient or outpatient Patients who have a history of intestinal resection (other than appendiceal resection) Patients who have a complication of malignant tumor Female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>OPC-6535</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>